CClinicalTrials.gg
WithdrawnNCT02810522Updated Nov 15, 2019

OneTouch Select® [Brand Name]Plus Blood Glucose Monitoring System(BGMS) Registration Study

An interventional study of OneTouch Select® Plus Glucose Test Strips in Blood Glucose Measurement, sponsored by Johnson & Johnson Medical, China. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-15.

Sponsored by Johnson & Johnson Medical, China · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to support the regulatory application of OneTouch Select® Plus test strips in China. The blood glucose test strip is regulated as an In Vitro Diagnostic (IVD) product and China Food and Drug Administration (CFDA) regulation of IVDs should be complied with. The result of this study will be used to support regulatory filing in China.

Investigational Product:

OneTouch Select® Plus test strips (test with OneTouch Select® Plus glucose meter)

Objectives:

  1. Assess Lay User and Health Care Professional (HCP) fingertip test results obtained on OneTouch Select® Plus BGMS compared to a validated method (YSI 2300 glucose analyzer results), according to International Standards Organization( ISO) 15197:2003(E) section 8.0 and ISO 15197:2013(E)
  2. Lay User System Use evaluation.
  3. Assess the effectiveness of the instructions for use of OneTouch Select® Plus BGMS (Owner's booklet) and insert of test strips for the lay user.

Comparator(control) Product:

YSI 2300 glucose analyser

Acceptance Criteria:

User Performance of the OneTouch Select® Plus Blood Glucose Monitoring system(described as OneTouch Select Plus below) is met if the lay user and HCP results obtained with OneTouch Select Plus meet the requirement stated in section 7.4.1 of ISO () 15197:2003(E). Further to meet the requirements of ISO 15197:2013(E) , the lay user results obtained with OneTouch Select Plus should meet the requirements stated in section 8.2 of ISO 15197:2013(E). The effectiveness of instructions for use is met , if for each item on the Instructions for Use Questionnaire, the 90% lower confidence limit (90% LCL) for the correct response rate is equal to or greater than 70%.

Study Design and subject population:

This study is an open, non-randomized clinical evaluation and will be conducted at a minimum of 2 sites in China. At least 240 evaluable diabetic subjects who meet the enrolment criteria will participate in this evaluation.

Study procedures:

  1. Each potential Subject (or legally authorized representative) reads and signs the Informed Consent Form, and receives a signed copy.
  2. After completing an in-clinic familiarization session, the Subject lances a fingertip, obtains a drop of blood large enough for two meter tests, and performs a self-test using OneTouch Select Plus BGMS.
  3. Study staff immediately performs a blood glucose test from the same blood drop with a second set of OneTouch Select Plus BGMS with the same lot of test strips.
  4. Within 5 minutes of the Subject's self-lancing, study staff collects blood from the same finger puncture for hematocrit and reference plasma glucose testing (duplicate tests on the YSI 2300 performed by study staff).
02

Conditions studied

  • Blood Glucose Measurement
03

In context

Lead sponsor

Johnson & Johnson Medical, China is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Subject is at least 18 years of age.
  2. Subject has a current diagnosis of type 1 or type 2 diabetes mellitus.
  3. Subject is currently performing unassisted self-monitoring of blood glucose.
  4. Subject agrees to sign two (2) copies each of the Subject Informed Consent Form.
  5. Subject agrees to provide relevant demographic, medical history and diabetes management information and agrees to allow study staff access to medical records when necessary.
  6. Subject can read and understand Chinese.
  7. Subject agrees to complete all aspects of the study including at least one fingertip puncture, one retry in maximum may be performed if insufficient blood collected or an error message is obtained on the first attempt.

Exclusion criteria

Exclusion Criteria:

  1. Subject is currently working for, has previously worked for, or has an immediate family member working for a company manufacturing and/or marketing blood glucose monitoring products.
  2. Subject has already participated in this study.
  3. Subject is knowingly pregnant.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

  • DeviceOneTouch Select® Plus Glucose Test Strips
06

What researchers measure

Primary outcomes

  1. The accuracy of glucose results obtained from OneTouch Select Plus BGMS

    User Performance of the OneTouch Select® Plus Blood Glucose Monitoring system(described as OneTouch Select Plus below) is met if the lay user and HCP results obtained with OneTouch Select Plus meet the requirement stated in section 7.4.1 of ISO 15197:2003(E).Further to meet the requirements of ISO 15197:2013(E) , the lay user results obtained with OneTouch Select Plus should meet the requirements stated in section 8.2 of ISO 15197:2013(E).

    Time frame: instantly after Glucose testing

  2. The correct response rate of Instructions for Use Questionnaire

    The effectiveness of instructions for use is met , if for each item on the Instructions for Use Questionnaire, the 90% lower confidence limit (90% LCL) for the correct response rate is equal to or greater than70%

    Time frame: instantly after Glucose testing

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02810522
Lead sponsor
Johnson & Johnson Medical, China
Collaborators
Shanghai 6th People's Hospital, Shanghai East Hospital
Responsible party
Sponsor
First posted
Jun 23, 2016
Start date
Aug 31, 2016
Primary completion
Nov 30, 2016 (estimated)
Completion
Mar 31, 2017 (estimated)
Last update
Nov 15, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion